Thursday
Jul242008
Do pharmaceutical companies hate sick children?
Thursday, July 24, 2008 at 12:53PM
Mustargen treats rare cancers, Cosmegen treats kidney disease and Matulane treats Hogdkins lymphoma. These miracle drugs have one thing in common. According to calculation from the Pharmaceutical Reseach in Management and Economics (PRIME) Institute, the prices of these drugs have seen increases as high as 8,000 percent.
The Joint Economic Committee held a hearing to examine the skyrocketing prices of certain prescription drugs and its impacts. U.S. Senator Amy Klobuchar (D-Minn.) said that she first became aware of the aggressive pricing practices when she found out the price for a drug used to treat patent ductus arteriosis (PDA), a disorder which prevents holes from healing in the hearts of infants, had increased substantially. According to Klobuchar, Ovation Pharmaceuticals acquired the rights to the drug and increased the price from $100 to $1,875 per three one-milligram units. Klobuchar pointed out that the price charged in the U.S. is 44 times higher than in Canada with no justification for the huge price disparity. Klobuchar also noted that Ovation Pharmaceuticals had been invited to participate in the hearing but had declined the offer.
Madeline Carpinelli, a research fellow at the PRIME Institute at the University of Minnesota, said that ‘extraordinary’ price increases for drug products have been observed in recent years. Carpinelli said that an ‘extraordinary’ price increase is a change of more than 100 percent at a single point in time with some ranging to more than 10,000 percent. Carpinelli emphasized that brand-name drug prices are growing at more than two and a half times the rate of general inflation.
Dr. Alan Goldbloom, president and Chief Executive Officer of Minnesota Children’s Hospital, discussed the drug Indocin used to treat PDA. According to Goldboom, when Ovation Pharmaceuticals bought exclusive rights to Indocin, the price for one unit of it jumped from $108 to $1,500 which is a 1,278 percent increase. Goldbloom was quick to point out that Indocin has been used for more than three decades as standard initial treatment so the dramatic price increase could not be attributed to the high cost of research and development. He also said that there are no other manufacturers of Indocin which means Ovation has a monopoly and can use it as a price-gouge.
Danielle Foltz, the mother of an infant diagnosed with Infantile Spasms, discussed the hurdles faced when trying to obtain the appropriate medication, Acthar gel, for her child. According to Foltz, Questcor Pharmaceuticals had raised the price per vial of the drug from $1,000 to over $30,000. Foltz had read that Questcor promised no child who truly needed the treatment would go without. When she called Questcor, she was told that the approval process would take three days without the guarantee of a positive outcome. Foltz said she was fortunate that their insurance covered her child’s treatment but she also noted that the price of Acthar gel is continuing to escalate.
The Joint Economic Committee held a hearing to examine the skyrocketing prices of certain prescription drugs and its impacts. U.S. Senator Amy Klobuchar (D-Minn.) said that she first became aware of the aggressive pricing practices when she found out the price for a drug used to treat patent ductus arteriosis (PDA), a disorder which prevents holes from healing in the hearts of infants, had increased substantially. According to Klobuchar, Ovation Pharmaceuticals acquired the rights to the drug and increased the price from $100 to $1,875 per three one-milligram units. Klobuchar pointed out that the price charged in the U.S. is 44 times higher than in Canada with no justification for the huge price disparity. Klobuchar also noted that Ovation Pharmaceuticals had been invited to participate in the hearing but had declined the offer.
Madeline Carpinelli, a research fellow at the PRIME Institute at the University of Minnesota, said that ‘extraordinary’ price increases for drug products have been observed in recent years. Carpinelli said that an ‘extraordinary’ price increase is a change of more than 100 percent at a single point in time with some ranging to more than 10,000 percent. Carpinelli emphasized that brand-name drug prices are growing at more than two and a half times the rate of general inflation.
Dr. Alan Goldbloom, president and Chief Executive Officer of Minnesota Children’s Hospital, discussed the drug Indocin used to treat PDA. According to Goldboom, when Ovation Pharmaceuticals bought exclusive rights to Indocin, the price for one unit of it jumped from $108 to $1,500 which is a 1,278 percent increase. Goldbloom was quick to point out that Indocin has been used for more than three decades as standard initial treatment so the dramatic price increase could not be attributed to the high cost of research and development. He also said that there are no other manufacturers of Indocin which means Ovation has a monopoly and can use it as a price-gouge.
Danielle Foltz, the mother of an infant diagnosed with Infantile Spasms, discussed the hurdles faced when trying to obtain the appropriate medication, Acthar gel, for her child. According to Foltz, Questcor Pharmaceuticals had raised the price per vial of the drug from $1,000 to over $30,000. Foltz had read that Questcor promised no child who truly needed the treatment would go without. When she called Questcor, she was told that the approval process would take three days without the guarantee of a positive outcome. Foltz said she was fortunate that their insurance covered her child’s treatment but she also noted that the price of Acthar gel is continuing to escalate.
Republicans: Our Energy Proposal Creates “Real Jobs”
“Innovation, conservation and production,” were the key messages coming from the Republican Study Committee and the Western Caucus as Congressional Republicans unveiled their alternative energy proposal today.
Congressman Tom Price (R-Ga.) said, “Republican are wholly committed to finding positive solution to the challenges we face. Like with the stimulus, like with the budget and now in contrast to the Democrats national energy tax we are here to offer our vision.”
The American Energy and Innovation Act, as the proposal will be labeled, will create jobs and reduce debt according to Republicans. The main aims outlined in this bill are to, “encourage innovation” by creating renewable fuel options and environmental jobs. “Promote conservation” by “providing incentives for easing energy demand and creating a cleaner, more sustainable environment” and “increase production” by making use of all available technology and resources.
Congressman Rob Bishop (R-Utah) said there were now “two roads” Americans could chose to tackle energy needs. “The Democrat road is saying it can’t work we are not even going to it, our road is saying we have the ideas now is the time to do it, said Bishop.
Adding that “The Democrats have already given us an option on energy issues that will cost individuals up to $3000...the Republican road we want to go down is one that actually grows our energy supply so that no-one is harmed and in fact we have the chance to reduce the cost of energy.”
Bishop compared the two strategies to the movie ‘Back to the Future’ saying, “Remember those sequels to ‘Back to the Future’ where there were the two worlds? Our world is the one where the McFly family is happy, the Democrat version is the one where Biff runs everything.”
Congressman Jim Jordan (R-Ohio) said the bill would be a “common sense act that is going to use our natural resources and our advanced technology to meet our energy needs and most importantly help our economy grow.”
In closing, Congressman John Fleming (R-La.) added, our vision “creates a vision for jobs, more jobs, not the so called paper mache jobs the green jobs, but real jobs created by industry.”